SYNTHESIS, CHARACTERIZATION AND IN VITRO STUDY OF N'-[(1E)-(2-HYDROXY-3-METHOXYBENZYLIDENE)PYRAZINE-2-CARBOHYDRAZIDE AGAINST MYCOBACTERIUM TUBERCULOSIS H37Rv AND DM97

Abstract

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (MTB), where pyrazinamide (PZA) is a first-line drug used in its treatment. New drug proposals are urgently needed, given the increased resistance to antimicrobials such as PZA. In this work, we have synthesized and characterized N'-[(1E)-(2-Hydroxy-3-methoxybenzylidene)pyrazine-2-carbohydrazide (C3), to evaluate its in vitro antituberculosis activity in MTB H37Rv (sensitive strain) and DM97 (PZA-resistant strain). C3 was synthesized and characterized by elemental analysis, UV-Vis, FT-IR and 1H/13C NMR. The compound C3 is a hydrazone derivative of PZA.
In the tetrazolium microplate assay (TEMA) performed on MTB H37Rv at pH 6.0 and 6.8, PZA was found to have greater antituberculosis activity than C3 in H37Rv, however, in DM97, C3 (MIC = 64 μg/mL at pH 6.0; MIC = 256 μg/mL at pH 6.8) presented greater antituberculosis activity than PZA (MIC > 800 μg/mL at pH 6.0; MIC > 800 μg/mL at pH 6.8), which demonstrates the antituberculosis potential of C3 against this PZA-resistant strain.